The detectability of kratom in urine drug screenings is a key consideration for individuals who consume this botanical substance. Standard drug tests typically do not include specific assays for kratom alkaloids, such as mitragynine and 7-hydroxymitragynine, the primary active compounds. Therefore, routine panels designed to identify substances like opioids, benzodiazepines, or amphetamines will not register a positive result due to kratom consumption.
The absence of kratom detection in standard drug tests stems from several factors, including cost, the relative infrequency of kratom testing compared to other substances, and the lack of widespread regulatory requirements mandating its inclusion. Specific kratom testing is available, but its use is usually limited to forensic, clinical, or research settings. Understanding these limitations is essential for both employers and individuals concerned about potential drug screenings.